Effectiveness of combined chloroquine and primaquine treatment in 14 days versus intermittent single dose regimen, in an open, non-randomized, clinical trial, to eliminate Plasmodium vivax in southern Mexico

Table 5 Parameters of primary and recurrent Plasmodium vivax blood infections from ISD patients

Patient	Age/sex	Primary blood infection		Recurrent infection by microscopy				Serology (ELISA OD value/405NM; cut off value 0.25)
Patient	Age/sex	(p/µl) asexual parasitaemia	RFLP: cspr-msp3α/β	Day^a	Clinical symptoms	(p/µl) asexual parasitaemia	Genotype cspr-msp3α/β	Serology (ELISA OD value/405NM; cut off value 0.25)
P6	3/F	2364	vk247-A	D241^b	Yes	875	vk247-A	0.16_D211 → 2.57 _D241
P7	17/F	10,766	vk210-B/III	D236^b	Yes	14,218	vk210-B/III	0.04_D218 → 1.49 _D236
P15	62/F	675	vk210-B/IV	D312^b	Yes	246	vk210-B/IV	0.29_D301 → > 3.0_D312
P17	36/F	480	vk210/247-B/III	D108^b	Yes	8485	vk247-A/I	0.18_D89 → 2.1_D209
P35	20/F	2241	vK210-C/V	D336^b	Yes	846	vK210-C/V	0.18_D308 → 1.88_D336
P37	9/M	17,598	vK210-C/V	D287^b	Yes	866	vK210-C/V	0.16_D287 → 1.67_D308
P44	60/M	2951	vk210-C/VI	D282^b	Yes	844	vk210-C/VI	0.18_D244 → 0.53_D282
P56	42/F	7960	vk210-C/V	D178^b	Yes	1570	vk210/247-A/I	0.41_D147 → 1.12_D178
P62	26/M	4319	vk210/247-C/II	D216^b	Yes	2594	vk210-C/II	0.15_D183 → 2.48 _D216
P72	12/M	8059	vk210-B/III	D98^c	Yes	3505	vk210-B/III	0.963_D92 → 2.03_D98

Truncated (complete information is given in Additional file 6)
M male, F female, RFLP restriction fragment length polymorphism, cspr circumsporozoite gene central repeat type, msp3α merozoite surface protein 3α/β genes
^aDay of sample collection
^bAfter diagnosed with P. vivax, T14 was administered
^cContinued the ISD treatment; P44, was the only patient that had a second recurrent episode after T14 was administered; D348 was positive by microscopy

ISSN: 1475-2875